JP2021505611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505611A5 JP2021505611A5 JP2020531104A JP2020531104A JP2021505611A5 JP 2021505611 A5 JP2021505611 A5 JP 2021505611A5 JP 2020531104 A JP2020531104 A JP 2020531104A JP 2020531104 A JP2020531104 A JP 2020531104A JP 2021505611 A5 JP2021505611 A5 JP 2021505611A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- ikk
- pharmaceutical
- treatment
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17205864.6A EP3494994A1 (en) | 2017-12-07 | 2017-12-07 | Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases |
| EP17205864.6 | 2017-12-07 | ||
| PCT/EP2018/084055 WO2019110832A1 (en) | 2017-12-07 | 2018-12-07 | Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505611A JP2021505611A (ja) | 2021-02-18 |
| JP2021505611A5 true JP2021505611A5 (https=) | 2022-01-11 |
| JP7527639B2 JP7527639B2 (ja) | 2024-08-05 |
Family
ID=60629504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531104A Active JP7527639B2 (ja) | 2017-12-07 | 2018-12-07 | 免疫疾患の予防または治療のためのｒｉｐｋ１阻害剤とｉｋｋ阻害剤の組み合わせ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200383995A1 (https=) |
| EP (2) | EP3494994A1 (https=) |
| JP (1) | JP7527639B2 (https=) |
| CN (1) | CN111670049A (https=) |
| CA (1) | CA3103847A1 (https=) |
| MX (1) | MX2020007036A (https=) |
| WO (1) | WO2019110832A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021046515A1 (en) * | 2019-09-06 | 2021-03-11 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| IL291665B2 (en) | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| JP2023502514A (ja) | 2019-11-26 | 2023-01-24 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤 |
| EP4209213A1 (en) * | 2022-01-05 | 2023-07-12 | Universität zu Köln | Signalling-pathway inhibitor combinations for use in the treatment of cancer diseases |
| WO2024170776A1 (en) | 2023-02-17 | 2024-08-22 | Universität Zu Köln | Triple kinase inhibition for the treatment of type i interferon response associated disorders |
| CN119064582B (zh) * | 2024-09-02 | 2025-05-27 | 南方医科大学南方医院 | RIPK1 O-GlcNAc糖基化抑制剂在制备增强肾细胞癌舒尼替尼敏感性药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03006817A (es) * | 2001-02-01 | 2003-11-13 | Bristol Myers Squibb Co | Metodo de tratamiento de enfermedades inflamatorias e inmunes usando inhibidores de la ikb cinasa (ikk). |
| JP2009539865A (ja) * | 2006-06-06 | 2009-11-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換３−アミノ−チエノ［２，３−ｂ］ピリジン２−カルボン酸アミド化合物及び製造方法及びそれらの使用 |
| ES2555160B1 (es) * | 2014-06-24 | 2016-10-25 | Aptus Biotech, S.L. | Aptámeros específicos de TLR-4 y usos de los mismos |
| EP3017825A1 (en) * | 2014-11-06 | 2016-05-11 | Ludwig-Maximilians-Universität München | An inhibitor of the RIPK1-dependent necrosis pathway and a pharmaceutical composition comprising the same |
-
2017
- 2017-12-07 EP EP17205864.6A patent/EP3494994A1/en not_active Withdrawn
-
2018
- 2018-12-07 CA CA3103847A patent/CA3103847A1/en active Pending
- 2018-12-07 EP EP18826203.4A patent/EP3720493B1/en active Active
- 2018-12-07 CN CN201880088634.3A patent/CN111670049A/zh active Pending
- 2018-12-07 US US16/769,972 patent/US20200383995A1/en active Pending
- 2018-12-07 WO PCT/EP2018/084055 patent/WO2019110832A1/en not_active Ceased
- 2018-12-07 MX MX2020007036A patent/MX2020007036A/es unknown
- 2018-12-07 JP JP2020531104A patent/JP7527639B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505611A5 (https=) | ||
| Li et al. | Microglial polarization in TBI: Signaling pathways and influencing pharmaceuticals | |
| Robert et al. | Characterization of the MMP/TIMP imbalance and collagen production induced by IL-1β or TNF-α release from human hepatic stellate cells | |
| Ma et al. | Proinflammatory effects of S100A8/A9 via TLR4 and RAGE signaling pathways in BV-2 microglial cells | |
| Egners et al. | The response of macrophages and neutrophils to hypoxia in the context of cancer and other inflammatory diseases | |
| McGeer et al. | The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases | |
| Zhu et al. | Gene silencing of NALP3 protects against liver ischemia–reperfusion injury in mice | |
| KR102760315B1 (ko) | C/EBP 알파 saRNA 조성물 및 사용 방법 | |
| Culig | Cytokine disbalance in common human cancers | |
| Pensa et al. | Stat3 and the inflammation/acute phase response in involution and breast cancer | |
| US8007790B2 (en) | Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases | |
| Grande | Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring | |
| Dong et al. | Inhalable siRNA targeting IL-11 nanoparticles significantly inhibit bleomycin-induced pulmonary fibrosis | |
| CN111741763B (zh) | 包含apl型肽的药用组合物 | |
| US9750718B2 (en) | Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity | |
| Araújo et al. | Protective effect of angiotensin II receptor blocker against oxidative stress and inflammation in an oral mucositis experimental model | |
| JP2013504603A5 (https=) | ||
| Zheng et al. | Pivotal role of cerebral interleukin-23 during immunologic injury in delayed cerebral ischemia in mice | |
| CN113750089B (zh) | 2-芳基-1,3二氢苯并咪唑衍生物在制备治疗慢性肝病的药物中的用途 | |
| CN115590880A (zh) | 工程化的巨噬细胞联用在治疗纤维化疾病中的应用 | |
| Huang et al. | IL-1 signaling pathway, an important target for inflammation surrounding in myocardial infarction | |
| Feng et al. | Senescence-and immunity-related changes in the central nervous system: A comprehensive review | |
| Haghikia et al. | Intracellular application of TNF-alpha impairs cell to cell communication via gap junctions in glioma cells | |
| US20180002698A1 (en) | C-rel-specific sirna and its use for preventing and treating autoimmune psoriasis | |
| US11628163B2 (en) | 1-piperidinepropionic acid for treating a fibrosing disease |